NEWS COMMENTARY

Geltor raises $91.3 million to expand fermentation-derived collagen applications

Published:
July 30, 2020
Coverage:
Accelerating Materials Innovation More...
Activities:
Investment
Very important

The Series B funding round was led by CPT Capital, with participation from a number of other previous investors, bringing Geltor's total funding to date to about $116 million. The company will use these funds for scaling up production and expanding applications of its structural protein ingredients like collagen and elastin. Aside from its recent momentum in the cosmetics space, Geltor is also looking to launch ingestible collagen supplements with functional health impacts as well as food and beverage ingredients by 2021, indicating sustained interest in the cellular agriculture space. Clients, synthetic biology and fermentation enable alternative manufacturing methods capable of addressing the evolving needs of consumer-facing businesses.

For the original news article, click here .


Further Reading

Perfect Day rakes in $140 million Series C round led by Temasek, bringing total funding to more than $200 million

News Commentary | December 13, 2019

The funding comes just a few weeks after the company announced it is expanding into dairy fats. While this event is a win for cellular agriculture, it underscores the capital‑intensive nature of scaling the production approach. As a reference, the most highly funded plant‑based dairy company, Ripple... Not part of subscription

Chr. Hansen enters the human milk oligosaccharide space through Jennewein acquisition

News Commentary | September 28, 2020

Major ingredient player Chr. Hansen has agreed to buy German company Jennewein Biotechnologie for $364 million as it looks to enter the human milk oligosaccharide (HMO) market. This move is in line with the company's 2025 strategy to strengthen its offerings related to fermentation technology ... Not part of subscription

Mycoproteins gain funding momentum as The Protein Brewery raises $22 million Series A

News Commentary | November 12, 2020

This Series A round was led by Novo Holdings, joined by Roquette Ventures and Unovis Asset Management, and will help the Dutch startup to focus on R&D as well as scale up production of its mycoprotein ingredient "Fermotein." It hopes to commercialize Fermotein upon regulatory approval by 2021 in... To read more, click here.